CMN Weekly (19 April 2024) - Your Weekly CRISPR...
CMN Weekly
Apr. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Moderna Therapeutics
Main (gene editing) focus: Next-generation in vivo gene-editing therapeutics
Company stage: Commercial
Diseases: Undisclosed
Genome editing tool: Undisclosed
Funding stage: Public (NASDAQ:MRNA)
Location: Cambridge, MA, USA
Website: https://www.modernatx.com/
Pipeline: https://www.modernatx.com/pipeline
Partners: Metagenomi
Moderna Therapeutics is a vaccine developer, mostly known for its involvement and efforts in the development and commercialisation of its mRNA-based COVID-19 vaccine. In relation to genome editing, the company has disclosed a collaboration with Metagenomi to develop next-generation in vivo gene-editing therapeutics. The collaboration will see the use of Metagenomi's gene-editing platform in combination with Moderna's mRNA lipid nanoparticle (LNP) technologies to edit multiple udisclosed targets.
